SCHEMBL17428962

SCHEMBL17428962

CCc1sc(C=O)cc1Cc1cccc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 3/20 0.39
MAPK1 P28482 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
ADCY10 Q96PN6 1/20 0.36
CCR2 P41597 1/20 0.36
DAO P14920 1/20 0.36
PTGER4 P35408 1/20 0.36
PNMT P11086 2/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17428965 0.90 LMNA (0.40) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL18995168 0.86 MAPT (0.38) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL17398353 0.86 TAAR1 (0.41) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL30579035 0.86 TAAR1 (0.41) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL17398436 0.86 LMNA (0.38) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL17398648 0.83 LMNA (0.41) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL17410226 0.83 PNMT (0.40) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL17398724 0.82 DAO (0.41) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL18995173 0.81 MAPT (0.38) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL17398263 0.81 CYP1A2 (0.39) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 US disclosed
US-20170216290-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-08-03 US disclosed
US-9683003-B2 Heteroaryl compounds useful as inhibitors of SUMO activating enzyme MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
US-20170002032-A9 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-01-05 US disclosed
US-20160009744-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002032-A9 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 LMNA 2130/4885MEN1 3957/4885ALDH1A1 1512/4885
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 LMNA 2130/4885MEN1 3957/4885ALDH1A1 1512/4885
US-20170216290-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 LMNA 2130/4885MEN1 3957/4885ALDH1A1 1512/4885
US-20160009744-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 LMNA 2130/4885MEN1 3957/4885ALDH1A1 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.